<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636686</url>
  </required_header>
  <id_info>
    <org_study_id>BMN-051-302</org_study_id>
    <nct_id>NCT02636686</nct_id>
  </id_info>
  <brief_title>Extension Study of Drisapersen in DMD Subjects</brief_title>
  <official_title>An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in Subjects With Duchenne Muscular Dystrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This is a phase IIIb, multi-centre, open-label extension study in male subjects with DMD who
      previously have been treated with drisapersen, aiming at assessing the safety and efficacy of
      drisapersen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIIb, multi-centre, open-label extension study in male subjects with DMD who
      have previously been treated with drisapersen.

      This study aims to enroll up to approximately 220 subjects. The primary dosing arm is
      drisapersen 6 mg/kg as subcutaneous (SC) injection(s) once a week. All subjects starting with
      subcutaneous injections will receive a loading dose of twice weekly 6mg/kg drisapersen for
      the first three weeks of treatment. This study does not have a minimum duration of
      participation. Subjects will have varying times of study participation depending on when they
      enter from one of the eligible studies and will be permitted to continue the study until such
      a time that they withdraw based on protocol-defined criteria, or BioMarin stops the study.
      Subjects naïve to treatment are not eligible for participation in this study

      For subjects who have previously experienced significant safety or tolerability issues in one
      of the eligible studies, or who experience these during this study, there is the potential of
      an alternate intermittent dosing arm. This will be agreed in advance with the Medical
      Monitor.

      For subjects who have previously experienced significant injection site reactions in an
      earlier drisapersen study, or who experience similar reaction(s) during this study, there is
      the potential to be dosed intravenously.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <why_stopped>
    Due to a company decision to stop the development of exon-skipping Duchenne muscular dystrophy
    therapy.
  </why_stopped>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Duchenne Muscular Dystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drisapersen</intervention_name>
    <description>Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg</description>
    <other_name>PRO051</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any subject who has been previously treated with an exon 51 skipping antisense
             oligonucleotide (drisapersen or eteplirsen) and is not eligible for another ongoing
             drisapersen study. Subjects who withdrew from the previous studies due to meeting
             laboratory safety stopping criteria may be eligible to enroll if:

          2. The laboratory parameters that led to stopping have resolved; benefit of further
             treatment with drisapersen outweighs the risk to the individual subject; and following
             consultation with the Medical Monitor.

          3. Subjects with DMD mutation/deletion within the dystrophin gene and correctable by
             drisapersen-induced DMD exon 51 skipping.

          4. Male subjects age &gt;5 at screening in whom the investigator considers treatment with
             drisapersen is likely to lead to improvement or prevent worsening of the condition.

          5. Continued use of glucocorticoids for a minimum of 60 days prior to study entry with a
             reasonable expectation that the subject will remain on glucocorticoids for the
             duration of this study. Changes to or cessation of glucocorticoids will be at the
             discretion of the investigator conducting this study in consultation with the
             subject/parent and Medical Monitor.

          6. Willing and able to comply with all study requirements and procedures (with the
             exception of those assessments requiring a subject to be ambulant, for those subjects
             who have lost ambulation).

          7. Able to give informed assent and/or consent in writing by the subject and/or
             parent(s)/legal guardian (according to local regulations)

        Exclusion Criteria:

          1. Subjects who have previously been treated with drisapersen and who had a serious
             adverse experience or who met safety stopping criteria that remains unresolved, which
             in the opinion of the investigator could have been attributable to drisapersen. Once
             resolved, subject may be eligible to enter the study following investigator
             consultation with the Medical Monitor.

          2. Use of anticoagulants, anti-thrombotics or antiplatelet agents within 28 days of the
             first re-dosing of drisapersen. Chronic use of anticoagulants, anti-thrombotics or
             antiplatelet agents is prohibited during the study. As needed dosing (pro re nata -
             PRN) may be acceptable (except for aspirin) following discussion with the Medical
             Monitor.

          3. Participation in any investigational clinical trial within 3 months prior to start or
             during this study (except for other drisapersen studies). If subjects have
             participated in any other study within the last 6 months this should be discussed with
             the Medical Monitor prior to start of this study.

          4. History of significant medical disorder which may confound the interpretation of
             safety data (e.g. current or history of renal or liver disease/impairment, history of
             inflammatory illness)

          5. Symptomatic cardiomyopathy. If subject has a left ventricular ejection fraction &lt;45%
             at start of this study, the investigator should discuss inclusion of subject in this
             study with the Medical Monitor.

          6. A platelet count under the lower limit of normal (LLN) at start of this study. A
             re-test is possible at a later stage, and if within normal range, the subject may
             enter the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derry Ridgway, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMAI Research</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hosital, Children's Neuroscience Centre</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neuromuscular Research</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Fabiola Children's University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent, Afdeling Neurologie</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Citadelle, Centre de référence des Maladies</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Alexandrovska</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detska Nemocnice</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Motol</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital</name>
      <address>
        <city>Bayern</city>
        <state>Muenchen</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah, Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Ospedaliera</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization</name>
      <address>
        <city>Saitama</city>
        <zip>349-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center Hospital of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCN St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPCSK Uniwersytet Medyczny w</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Pediatrics and Children</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Children's Hospsital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Institute of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Drisapersen</keyword>
  <keyword>Kyndrisa</keyword>
  <keyword>exon-skipping</keyword>
  <keyword>exon-51</keyword>
  <keyword>BMN-051-302</keyword>
  <keyword>051-302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

